| Previous Close | 72.95 |
|---|---|
| Bid | 72.67 x 800 |
| Ask | 72.68 x 900 |
| Day's Range | 72.48 - 73.26 |
| 52 Week Range | 53.22 - 80.59 |
What are analysts' price targets for Bristol-Myers Squibb's stock?
13 equities research analysts have issued twelve-month price targets for Bristol-Myers Squibb's stock. Their predictions range from $46.36 to $63.00. On average, they expect Bristol-Myers Squibb's share price to reach $56.03 in the next twelve months.
What is the all-time high and low for Bristol Myers Squibb?
The all-time high Bristol Myers Squibb stock closing price was 77.94 on October 28, 1999. The Bristol Myers Squibb 52-week high stock price is 69.75, which is 9.8% above the current share price. The Bristol Myers Squibb 52-week low stock price is 53.22, which is 16.2% below the current share price.
What are the products of Bristol-Myers Squibb Company?
Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500. Analyst Report: Bristol-Myers Squibb Co. Bristol-Myers Squibb is a leading worldwide biopharmaceutical company.
Is Bristol-Myers Squibb in the S&P 500?
BMY shares are a component of the S&P 500. Analyst Report: Bristol-Myers Squibb Co. Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019.
See more
How much is Bristol Myers stock today?
$72.95$ 72.95CloseChgChg %$72.95-0.09-0.12%3 days ago
Is Bristol Myers a value stock?
The chart has 1 X axis displaying Time. Range: 2022-07-22 09:23:42 to 2022-07-22 20:05:17. The chart has 1 Y axis displaying values. Range: 72 to 74....Bristol Myers Squibb Co.Volume13.5MMarket Value$155.32BShares Outstanding2.13BEPS (TTM)$2.82P/E Ratio (TTM)25.897 more rows
Is BMY a buy today?
No, in September 2021, BMY stock isn't a buy.
When did Bristol Myers stock split?
Squibb Corporation Corporate ActionsRecord DateDescriptionMay 20, 1974Stock splitJanuary 2, 1987Westmark International spin off from Squibb Corp.June 1, 1987Stock splitOctober 4, 1989Squibb Corporation and Bristol-Myers Company merged to form Bristol-Myers Squibb Company1 more row
Does Bristol-Myers pay a dividend?
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable June 1, 2022, to stockholders of record at the close of business on May 10, 2022.
Is Bristol-Myers Squibb part of Pfizer?
Bristol-Myers Squibb will make an upfront payment of $50 million to Pfizer as part of this agreement. The companies will share all development and commercialization expenses along with profits/losses on a 60%-40% basis, with Pfizer assuming the larger share of both expenses and profit/losses.
Will BMY stock go up?
Stock Price Forecast The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 82.00, with a high estimate of 92.00 and a low estimate of 63.00. The median estimate represents a +12.42% increase from the last price of 72.94.
What is Bristol-Myers known for?
The company is known for biological and pharmaceutical research, producing the antipsychotic Abilify (which it helps market) and its blood thinners Plavix and Eliquis, as well as cancer drug Opdivo.
Is Bristol-Myers Squibb a good company?
Bristol-Myers Squibb has an overall rating of 4.1 Average Rating out of 5, based on over 196 Bristol-Myers Squibb Review Ratings left anonymously by Bristol-Myers Squibb employees, which is 5% higher than the average rating for all companies on CareerBliss.
What is the purpose of splitting stock?
A stock split allows a company to break each existing share into multiple new shares without affecting its market capitalization (total value of all its shares) or each investor's stake in the company. A stock split can be a good sign for both current and prospective shareholders.
How many times has BMY split?
Bristol Myers Squibb (BMY) has 6 splits in our Bristol Myers Squibb stock split history database. The first split for BMY took place on May 31, 1977.
Is BBY a good stock to buy?
Out of 13 analysts, 5 (38.46%) are recommending BBY as a Strong Buy, 1 (7.69%) are recommending BBY as a Buy, 6 (46.15%) are recommending BBY as a Hold, 0 (0%) are recommending BBY as a Sell, and 1 (7.69%) are recommending BBY as a Strong Sell.
Is BMY undervalued?
That said, BMY stock looks undervalued at its current levels of $55. Going by our Bristol Myers Squibb Valuation of $79 per share, based on $7.52 expected adjusted EPS and around 10x P/E multiple for 2021, there is an upside potential of 45% from its current levels.
Is Bristol Myers Squibb a good company?
Bristol-Myers Squibb has an overall rating of 4.1 Average Rating out of 5, based on over 196 Bristol-Myers Squibb Review Ratings left anonymously by Bristol-Myers Squibb employees, which is 5% higher than the average rating for all companies on CareerBliss.
Should you buy the dip stocks?
A stock that has returned 20 percent annually for 20 years will likely return to that average over time, and by buying the dip, you may be able to actually earn even more than that 20 percent. But you'll only get that attractive long-term return if you buy and hold your stocks or index funds.
Is Bristol-Myers Squibb stock a Buy, Sell or Hold?
Bristol-Myers Squibb stock has received a consensus rating of buy. The average rating score is and is based on 13 buy ratings, 10 hold ratings, and...
What was the 52-week low for Bristol-Myers Squibb stock?
The low in the last 52 weeks of Bristol-Myers Squibb stock was 53.22. According to the current price, Bristol-Myers Squibb is 141.09% away from the...
What was the 52-week high for Bristol-Myers Squibb stock?
The high in the last 52 weeks of Bristol-Myers Squibb stock was 78.60. According to the current price, Bristol-Myers Squibb is 95.53% away from the...
What are analysts forecasts for Bristol-Myers Squibb stock?
The 25 analysts offering price forecasts for Bristol-Myers Squibb have a median target of 68.57, with a high estimate of 92.00 and a low estimate o...
What is a key stat?
What is BMS pharmaceutical?
Key stats. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City.
Where is BMS located?
About. . Bristol Myers Squibb is an American multinational pharmaceutical company , headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
Where is BMS headquartered?
Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City . BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations.
How much does Bristol Myers Squibb make?
Reported on 4/28/21. Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City . BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
What is the company that makes Revlimid?
Bristol-Myers Squibb has a market capitalization of $150.94 billion and generates $42.52 billion in revenue each year. The biopharmaceutical company earns $-9,015,000,000.00 in net income (profit) each year or $6.44 on an earnings per share basis.
What is the consensus rating for Bristol Myers Squibb?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
When is Bristol Myers Squibb's dividend?
Bristol-Myers Squibb has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.
Does Bristol Myers have a dividend?
Bristol-Myers Squibb announced a quarterly dividend on Thursday, June 17th. Shareholders of record on Friday, July 2nd will be given a dividend of $0.49 per share on Monday, August 2nd. This represents a $1.96 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Thursday, July 1st.
What time do you trade in the pre market?
Bristol-Myers Squibb does not yet have a strong track record of dividend growth. The dividend payout ratio of Bristol-Myers Squibb is 30.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 24.32% next year.
What is the focus of Bristol Myers Squibb?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Does market cap include convertible securities?
A key focus for Bristol is immuno-oncology, where the firm is leading in drug development.
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
Biohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses.
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Ownership
- Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol \"BMY.\" Bristol-Myers Squibb saw a increase in short interest in April. As of April 15th, there was short interest totalling 77,458,472 shares, an increase of 61.2% from the March 29th total of 48,063,938 shares. Based on an average daily volume of 18,421,723 shares, the short-interest ra…
Results
- Bristol-Myers Squibb Co (NYSE:BMY) posted its earnings results on Thursday, April, 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.09 by $0.01. The biopharmaceutical company earned $5.92 billion during the quarter, compared to analysts' expectations of $5.72 billion. Bristol-Myers Squibb had a return on equity …
Release
- Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Bristol-Myers Squibb.
Sales
- Bristol-Myers Squibb updated its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.18. Bristol-Myers Squibb also updated its FY 2019 guidance to $4.10-4.20 EPS.
Ratings
- 16 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Bristol-Myers Squibb in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Bristol-Myers Squibb.
Reception
- Press coverage about BMY stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a new…
Business
- Bristol-Myers Squibb has a market capitalization of $76.89 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.
Location
- Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected].